Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,482 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).
Cho JH, Lim SH, An HJ, Kim KH, Park KU, Kang EJ, Choi YH, Ahn MS, Lee MH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Cho JH, et al. Among authors: choi yh. J Clin Oncol. 2020 Feb 10;38(5):488-495. doi: 10.1200/JCO.19.00931. Epub 2019 Dec 11. J Clin Oncol. 2020. PMID: 31825714 Free PMC article. Clinical Trial.
A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Choi YH, Oh SC, Kim JS, Nam SH, Kim BS, Cho SH, Chung IJ, Song EK, Yim CY, Baek JH, Jeung HC, Hong YS, Yang SH, Kang HJ. Choi YH, et al. Cancer Chemother Pharmacol. 2012 Nov;70(5):665-72. doi: 10.1007/s00280-012-1956-1. Epub 2012 Aug 25. Cancer Chemother Pharmacol. 2012. PMID: 22926638 Clinical Trial.
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13.
Yoo KH, Lee SJ, Cho J, Lee KH, Park KU, Kim KH, Cho EK, Choi YH, Kim HR, Kim HG, Ahn HJ, Lee HY, Yun HJ, Kang JH, Jeong J, Choi MY, Jung SH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Yoo KH, et al. Among authors: choi my, choi yh. Cancer Res Treat. 2019 Apr;51(2):718-726. doi: 10.4143/crt.2018.324. Epub 2018 Sep 3. Cancer Res Treat. 2019. PMID: 30177585 Free PMC article. Clinical Trial.
Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
Park JH, You GL, Ahn MJ, Kim SW, Hong MH, Han JY, Ock CY, Lee JS, Oh IJ, Lee SY, Kim CH, Min YJ, Choi YH, Ryu JS, Park SH, Ahn HK, Shim BY, Lee KH, Lee SY, Kim JS, Yi J, Choi SK, An H, Kang JH. Park JH, et al. Among authors: choi sk, choi yh. J Cancer Res Clin Oncol. 2021 Aug;147(8):2459-2469. doi: 10.1007/s00432-021-03527-4. Epub 2021 Feb 1. J Cancer Res Clin Oncol. 2021. PMID: 33523301
Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22.
Jung HA, Hong MH, Lee HW, Lee KH, Kim IH, Min YJ, Ahn HK, Shim BY, Choi YH, Lee YG, Kim JA, Jang JS, Shin SH, Park KU, Kang JH, Park K. Jung HA, et al. Among authors: choi yh. Transl Lung Cancer Res. 2022 Jul;11(7):1369-1379. doi: 10.21037/tlcr-22-79. Transl Lung Cancer Res. 2022. PMID: 35958320 Free PMC article.
Analysis of Response and Progression Patterns of Tyrosine Kinase Inhibitors in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Post Hoc Analysis of Two KCSG Phase II Trials.
Kim Y, Keam B, Kang EJ, Kim JS, Kim HR, Lee KW, Kwon JH, Lee KE, Yang Y, Choi YH, Kim MK, Ji JH, Yun T, Choi MY, Lee KH, Kim SB, Ahn MJ. Kim Y, et al. Among authors: choi my, choi yh. Cancer Res Treat. 2024 Apr 15. doi: 10.4143/crt.2024.008. Online ahead of print. Cancer Res Treat. 2024. PMID: 38637966 Free article.
3,482 results